Background: Repeated administration of amphetamine elicits a progressive enhancement in behavioral and subjective responses to the drug and an increase in amphetamine-induced dopamine release. This enhancement is called sensitization and is able to induce changes in the response of the brain dopamine system to amphetamines mimicking certain aspects of dopaminergic dysfunction in schizophrenia. Objectives: We are conducting experiments using positron emission tomography (PET) and the D 2/3 receptor agonist radioligand [
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Janssen Cilag Benelux, Netherlands, Abstract Introduction: Data on clinical outcomes with long-acting antipsychotic treatment in young, newly diagnosed patients with schizophrenia is sparse. OBJECTIVES: To explore hospitalization, drug utilization and clinical outcomes from medical records of newly diagnosed schizophrenia patients during first 12 months of treatment with once-monthly paliperidone palmitate (PP). Methods: International, multicenter, retrospective, observational study. Outcomes presented: baseline (BL) characteristics and demographics, clinically relevant improvements in disease severity (ie ≥20% decrease in PANSS or BPRS total score or CGI-S Change≥-2 or CGI-C≥3, with no score showing worsening) and clinically relevant functional improvement (ie change in PSP total score≥+7 points or change in GAF total score≥+20 points, with no score showing worsening) from BL to last-observationcarried-forward endpoint (LOCF-EP) within 12-month documentation period, mean mode PP dose and adverse drug reactions. Results: 84 patients analyzed: 69% male, mean age at initiation of PP was 24.1(SD2.7) years, Mean BL weight was 78.7(SD16.0)kg and 80.0(SD14.7)kg at LOCF-EP, with a mean change of 1.2(SD3.9) kg; mean time from first psychotic episode to initiation of PP was 5.5(SD3.3) months. At LOCF-EP 86.6% achieved a clinically relevant improvement (71/84, Kaplan-Meier median time from initiation of PP: 52.4 days). 63.4% achieved a clinically relevant functional improvement (52/84, Kaplan-Meier median time from initiation of PP: 53.1 days). PP mean mode maintenance dose was 96.4(SD19.8) mg. ADRs reported in ≥5% of patients were weight increase 9.1% and hyperprolactinemia 5.7%. Conclusions: Treatment with once-monthly PP was well tolerated and associated with clinically relevant improvements in disease severity and functioning in young, newly diagnosed schizophrenia patients.
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Early schizophrenia patients treated with oncemonthly paliperidone palmitate over a 12-month period -A Retrospective Observational Study 
Abstract
Objective: To explore tolerability, safety and treatment response of flexibly-dosed paliperidone palmitate (PP) in adult patients hospitalized with an exacerbation of schizophrenia. Methods: International 6-week prospective open-label noninterventional study. Outcome parameters were changes in Brief Psychiatric Rating Scale (BPRS) total score, Clinical Global Impression-Severity Scale (CGI-S), Personal and Social Performance Scale (PSP), treatment satisfaction (Medication Satisfaction Questionnaire (MSQ)), Extrapyramidal Symptom Rating Scale (ESRS) scores and treatment-emergent adverse events (TEAEs) from baseline to last-observation-carried-forward endpoint. Results: 367 patients (65.9% male, mean age (±SD) 39.8 ± 12.1 years, 85.8% paranoid schizophrenia) were documented. 91.6% of patients completed the 6-week observation period. Most frequent reasons for early discontinuation were loss to follow-up (2.7%) and withdrawal of consent (1.6%). The recommended PP initiation regimen (150 mg eq on day 1 and 100 mg eq on day 8, both in the deltoid muscle) was used in 88.8% of subjects. Mean time from hospital admission to initiation of PP was 9.4 ± 7.7 days. Mean baseline BPRS total score of 50.2 ± 13.6 improved by -6.5 ± 8.6 at day 8 and by -19.3 ± 12.6 from baseline to endpoint; 95% confidence interval [CI]-20.7;-18.0; both p<0.0001. At endpoint, 93.6% of patients were rated as improved in CGI-S. Functioning in PSP significantly improved from 49.4 ± 14.7 at baseline by 14.3 ± 12.4 at endpoint (95% CI 12.9;15.8, p<0.0001). Mean ESRS total score significantly decreased from 3.7 ± 5.9 at baseline to 2.0 ± 4.7 at endpoint (p<0.0001). 6.0% of patients were very or extremely satisfied with their previous antipsychotic medication at baseline, which increased to 46.1% with PP at endpoint. TEAEs reported in ≥2% of patients were tremor (2.5%) and schizophrenia (2.2%). Conclusions: These data support results from previous randomized controlled and pragmatic studies that flexibly dosed paliperidone palmitate is well tolerated and associated with an early and clinically meaningful treatment response and functional improvement in patients hospitalized for an exacerbation of schizophrenia. Abstract Background: Reliable biology indicators for stress reaction and psychopathology are valuable markers for both psychological research and clinical practice. Recently, the measurement of salivary alpha-amylase (sAA) was introduced as a non-invasive and more convenience protocol. Several studies showed the high sensitivity of sAA level in various mental disorders, unfortunately there still no data on how the level of sAA in naïve-drugs of schizophrenia patients. Objective: To determine whether sAA level could be as potential biomarker for therapeutic response in schizophrenia patients. Methods: Using the cohort study, we collected 30 samples that met the inclusion criteria and 30 normal control samples.sAA level and PANSS score were taken 5 times at baseline, 3 days after treatment of antipsychotics, 5 days after treatment, 7 days, and 14 days after treatment of antipsychotics. Results: Schizophrenia patients showed significant higher sAA levels compared to normal control group. sAA levels showed significant decline in correlation with the improvement of PANSS score within 2 weeks of antipsychotics therapy. Conclusion: The measurement of sAA levels can be used as potential biomarker of therapeutic response in schizophrenia patients. Key word: schizophrenia, naïve-drugs, PANSS, sAA, antipsychotic
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